Cabozantinib-Treated RCC Medication Savings with TheDrugClub
Discount pricing may be available. Current formulary eligibility is being verified; a condition association does not establish FREE coverage.
- Join TheDrugClub as a member
- Receive your member card by email
- Present your card at a participating pharmacy
- Check active-formulary eligibility or available discount pricing
About Cabozantinib-Treated RCC
Renal Cell Carcinoma (RCC) is a type of kidney cancer, and for many, cabozantinib (brand name Cabometyx) is a vital treatment, especially in advanced stages. This powerful medication can be expensive, but TheDrugClub offers a simple way to significantly reduce your prescription costs, helping you focus on your health, not your budget.
Renal Cell Carcinoma (RCC) is the most common type of kidney cancer in adults. It originates in the lining of the small tubes in the kidney, which filter waste from the blood. While early-stage RCC can often be treated with surgery, advanced or metastatic RCC – meaning the cancer has spread to other parts of the body – presents a greater challenge. For these patients, systemic therapies are crucial to help control the disease and improve quality of life.
One such targeted therapy is cabozantinib, often prescribed under the brand name Cabometyx. Cabozantinib is a tyrosine kinase inhibitor (TKI) that works by blocking several proteins involved in cancer cell growth, survival, and blood vessel formation that feeds tumors. It's commonly used for advanced RCC, particularly after prior anti-angiogenic therapy, or as a first-line treatment for intermediate or poor-risk patients. While effective, like all powerful medications, it can come with side effects, and adherence to the prescribed regimen is key to its success.
Other treatments for RCC can include other targeted therapies, immunotherapies, and sometimes chemotherapy or radiation. The choice of treatment
The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.